Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?

Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?

Abstract Background Allergic bronchopulmonary aspergillosis (ABPA) is a severe hypersensitivity reaction to aspergillus species colonizing the airways of patients with asthma or cystic fibrosis. Biologics including anti-IgE and anti-IL5 antibodies have strongly changed the treatment of severe asthma...

Full description

Bibliographic Details
Main Authors: Carlo Mümmler, Bernd Kemmerich, Jürgen Behr, Nikolaus Kneidinger, Katrin Milger
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
ABPA
Aspergillosis
Asthma
Dupilumab
IL13
IL4
Online Access:http://link.springer.com/article/10.1186/s13223-020-00454-w

Internet

http://link.springer.com/article/10.1186/s13223-020-00454-w

Similar Items